Edwards Lifesciences (EW)
What changed in recent filings
- Institutions — 3 new · 2 added · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Edwards Lifesciences
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 2 → 2026 Q2: 6 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Edwards Lifesciences
Institutions we track that reported holding this stock in their most recent 13F.
- Baillie Gifford & Co0.10% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.10% of portfolio · since 2020 Q3
- Point72 Asset Management0.18% of portfolio · since 2024 Q4
- Caisse de depot (Quebec)0.12% of portfolio · held as of 2026 Q2 or earlier
- PRIMECAP Management0.18% of portfolio · held as of 2026 Q2 or earlier
- National Pension Service (Korea)0.06% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Edwards Lifesciences is classified under the Biotech & Health sector. See peers below.
ETFs holding Edwards Lifesciences
Per SEC N-PORT · 2026-06-30 · by weight · factual
EW on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
EW FAQ
What is Edwards Lifesciences (EW)?
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
What sector is Edwards Lifesciences in?
Edwards Lifesciences is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
Where can I analyze Edwards Lifesciences (EW) stock?
On Stocklore you can see EW's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.